

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

13281 U.S. PTO
102703

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	A2778B
First Inventor	Hong LI
Title	Adenovirus-mediated Intratumoral Delivery of an ...
Express Mail Label	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original, and a duplicate for fee processing)
2. Applicant claims small entity status.
See 37 CFR 1.27.
3. Specification [Total Pages 47]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 11]
5. Oath or Declaration [Total Pages]
 a. Newly executed (original or copy)
 b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
 - i. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. Application Data Sheet. See 37 CFR 1.76

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

 Continuation Divisional Continuation-in-part (CIP) of prior application No.: 09/403,736

Prior application information: Examiner Scott David PRIEBE Group / Art Unit: 1632


For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number:	29693	or <input type="checkbox"/> Correspondence address below
Name _____		
Address _____		
City _____	State _____	Zip Code _____
Country _____	Telephone _____	Fax _____

Name (Print/Type) David J. Kulik

Registration No. (Attorney/Agent) 36,576

Signature 

Date 10/27/2003

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete. Any including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

22386 U.S.P.T.O. 88988
10/693688

10/27/03

PATENT APPLICATION TRANSMITTAL LETTER
(Large Entity)

Docket No.
A2778B

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

For: **ADENOVIRUS-MEDIATED INTRATUMORAL DELIVERY OF AN ANGIOGENESIS ANTAGONIST FOR THE TREATMENT OF TUMORS**

Enclosed are:

- Certificate of Mailing with Express Mail Mailing Label No. _____
 _____ sheets of drawings.
 A certified copy of a _____ application.
 Declaration Signed. Unsigned.
 Power of Attorney
 Information Disclosure Statement
 Preliminary Amendment
 Other: Application Data Sheet

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	26	- 20 =	6	x \$18.00	\$108.00
Indep. Claims	4	- 3 =	1	x \$86.00	\$86.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
					BASIC FEE \$770.00
					TOTAL FILING FEE \$964.00

- A check in the amount of _____ to cover the filing fee is enclosed.
 The Director is hereby authorized to charge and credit Deposit Account No. _____
as described below.
 Charge the amount of _____ as filing fee.
 Credit any overpayment.
 Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,
pursuant to 37 C.F.R. 1.311(b).

Dated: 10/27/03



Signature

David J. Kulik, Registration No. 36,576
Patent Administration
WILEY, REIN & FIELDING
1776 K Street, N.W.
Washington, D.C. 20006

CC:



1776 K STREET NW
WASHINGTON, DC 20006
PHONE 202.719.7000
FAX 202.719.7049

Virginia Office
7925 JONES BRANCH DRIVE
SUITE 6200
MCLEAN, VA 22102
PHONE 703.905.2800
FAX 703.905.2820

www.wrf.com

October 27, 2003

David J. Kulik
202.719.7313
dkulik@wrf.com

VIA HAND DELIVERY

Commissioner for Patents
Alexandria, VA 22313-1450

Re: New U.S. Continuation Application of U.S. Serial No. 09/403,736 filed June 29, 2000
Inventors: Hong LI, et al.
Title: ADENOVIRUS-MEDIATED INTRATUMORAL DELIVERY OF AN ANGIOGENESIS ANTAGONIST FOR THE TREATMENT OF TUMORS
Attorney Docket No. A2778B

Dear Sir :

Please accord the enclosed application a filing date and serial number. Applicants await notification of a time period to file missing parts.

Applicants specifically incorporate by reference the prior application U.S. Serial No. 09/403,736.

The following are attached:

- 1) Utility Patent Application Transmittal Form (1 page)
- 2) Patent Application Transmittal Letter (1 page)
- 3) Application Data Sheet (5 pages)
- 4) Copy of original specification (cover sheet; pages 1-47 specification; 11 sheets of drawings); including: 3 pages claims; 1 page abstract;
- 5) Copy of Declaration filed June 29, 2000 (5 pages);
- 6) Preliminary Amendment filed October 26, 1999 (5 pages);
- 7) Information Disclosure Statement,(including 25 pages PTO-1449 and PTO-892); and
- 8) Stamped return receipt postcard.

Wiley Rein & Fielding LLP

Commissioner for Patents
October 27, 2003
Page 2

If an extension of time is required in the prior application, applicants hereby request an extension of time to enter and accord this application copending status with the prior application. The undersigned authorizes the Commissioner to charge Deposit Account No. 50-1129 for any extension of time fees.

Respectfully submitted,



David J. Kunk
Registration No. 36,576